{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095072","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.796710+00:00","generated_at":"2026-05-31T10:08:25.240079+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coya Q2 net loss $2.9M; FDA demands more data before COYA 302 ALS Phase 2","bullets":["Net loss $2.9M vs $3.1M YoY; collaboration rev $3.4M from Dr. Reddy's.","Cash $36.6M at June 30, 2024.","FDA requires additional non-clinical data before Phase 2 of COYA 302 in ALS; Coya plans to discuss in Q4 2024.","Received $5M strategic investment from ADDF for COYA 302 in FTD.","R&D expenses $4.6M (up from $1.1M) driven by preclinical costs for COYA 302."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095072","json":"https://secwatch.observer/filing/0000950170-24-095072.json","markdown":"https://secwatch.observer/filing/0000950170-24-095072.md","text":"https://secwatch.observer/filing/0000950170-24-095072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024095072/0000950170-24-095072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024095072/coya-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:08:25.240079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}